Skip to main content

Table 1 Pegfilgrastim administration options and their features*

From: Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia

Options for pegfilgrastim administration

Potential characteristics

Administration on the same day of myelosuppressive chemotherapy within a clinic, by a health professional.

▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection

▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection.

▪ No need to place the body injector for Neulastim®.

Administered when the patient returns to the clinic 24 h after myelosuppressive chemotherapy, specifically for the purpose of receiving an injection of pegfilgrastim, by a healthcare provider.

▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection.

▪ No need to place the body injector for Neulastim®.

Administered when the patient returns to the clinic 48–72 h after myelosuppressive chemotherapy, specifically for receiving an injection of pegfilgrastim, by a healthcare provider.

▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection

▪ No need to place the body injector for Neulastim®.

Administration at home using the Onpro Neulastim®™ kit (OBI) that has been attached to the patient’s arm or abdomen at the clinic; approximately 27 h (a little more than 1 day) after myelosuppressive chemotherapy.

▪ Not having to return to the clinic 24 h after chemotherapy to receive the injection

▪ Not having to return to the clinic 48–72 h after chemotherapy to receive the injection.

  1. *Adapted from (1)